Continuous glucose monitoring (CGM) among individuals with type 2 diabetes (T2D) and end-stage kidney disease (ESKD) on haemodialysis helps enhance the detection of hyperglycaemic and hypoglycaemic events, particularly nocturnal and prolonged episodes, suggests a study.